Cutaneous rash as a surrogate marker of time to tumor progression (TTP) with erlotinib in previously treated advanced non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Cedres Perez, S. [1 ]
Prat, A. [1 ]
Felip, E. [1 ]
Peralta, S. [1 ]
Perez, J. [1 ]
del Campo, J. [1 ]
Sala, G. [1 ]
Andreu, J. [1 ]
Pallisa, E. [1 ]
Baselga, J. [1 ]
机构：
[1] Vall dHebron Univ Hosp, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
19125
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with second-third line erlotinib
    Cedres, Susana
    Prat, Aleix
    Martinez, Pablo
    Pallisa, Esther
    Sala, Gemma
    Andreu, Jordi
    del Campo, J. M.
    Quispe, Isela
    Baselga, Jose
    Felip, Enriqueta
    LUNG CANCER, 2009, 66 (02) : 257 - 261
  • [22] Initial safety and efficacy results of erlotinib in previously treated patients with advanced non-small cell lung cancer
    Zhou, S.
    Zhou, C.
    Yan, L.
    Xu, Q.
    Xu, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [23] EXPERIENCE OF USING ERLOTINIB FOR TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Kanazawa, Kenya
    Ishida, Takashi
    Suzuki, Aya
    Tachihara, Motoko
    Minemura, Hiroyuki
    Sekine, Satoko
    Oshima, Kengo
    Yokouchi, Hiroshi
    Watanabe, Kana
    Tanino, Yoshinori
    Munakata, Mitsuru
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1310 - S1310
  • [24] Gastrointestinal hemorrhage in advanced non-small cell lung cancer (NSCLC) patients treated with erlotinib and celecoxib.
    Fidler, M. J.
    Argiris, A.
    Patel, J. D.
    Johnson, D. H.
    Sandler, A.
    Villaflor, V.
    Coon, J.
    Buckingham, L.
    Bonomi, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 407S - 407S
  • [25] Correlation between rash, hyperlipidemia, other characteristics and clinical outcome in patients with advanced non-small cell lung cancer (NSCLC) treated with erlotinib and bexarotene
    Cyrus, Jobin
    Dragnev, Konstantin H.
    DiSalvo, Wendye M.
    Rigas, James R.
    Dmitrovsky, Ethan
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S534 - S535
  • [26] Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)
    Rogado, J.
    Pacheco-Barcia, V.
    Fenor De la Maza, M. D.
    Serra, J. M.
    Toquero, P.
    Vera, B.
    Obispo, B.
    Mondejar, R.
    Ballesteros, A.
    Donnay, O.
    Colomer, R.
    Sanchez-Torres, J. M.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1915 - S1916
  • [27] Phase II pharmacodynamic trial of erlotinib in advanced non-small cell lung cancer (NSCLC) patients previously treated with platinum-based chemotherapy
    Felip, E
    Rojo, F
    Heller, A
    Foernzler, D
    Majo, J
    Klughammer, B
    Ramos, J
    Maacke, H
    Brennscheidt, U
    Baselga, J
    LUNG CANCER, 2005, 49 : S369 - S369
  • [28] PHASE II STUDY OF TWO ERIBULIN REGIMENS IN COMBINATION WITH ERLOTINIB IN PATIENTS (PTS) WITH PREVIOUSLY TREATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Geater, S. L.
    Ianotti, N.
    Thongprasert, S.
    Spira, A.
    Smith, D.
    Lee, V.
    Lim, W-T.
    Gopalakrishna, P.
    Reynolds, C.
    Mok, T. S. K.
    ANNALS OF ONCOLOGY, 2012, 23 : 393 - 393
  • [29] Erlotinib in previously treated non-small-cell lung cancer
    Shepherd, FA
    Pereira, JR
    Ciuleanu, T
    Tan, EH
    Hirsh, V
    Thongprasert, S
    Campos, D
    Maoleekoonpiroj, S
    Smylie, M
    Martins, R
    van Kooten, M
    Dediu, M
    Findlay, B
    Tu, DS
    Johnston, D
    Bezjak, A
    Clark, G
    Santabárbara, P
    Seymour, L
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (02): : 123 - 132
  • [30] Durvalumab (D) in combination with olaparib (O) for advanced, previously treated non-small cell lung cancer (NSCLC).
    Desmond, Daniel
    Vilimas, Rasa
    Mullenix, Cristina
    Zhao, Chen
    Szabo, Eva
    Shelat, Meenakshi
    Ballman, Madison
    Sansone, Susan
    Steinberg, Seth M.
    Lee, Jung-Min
    Rajan, Arun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345